Drug Delivery International Plans to Take University of Strathclyde Patents to the Next Stage
Published: Mar 15, 2011
The Glasgow-based firm – sister company of Bio-Images Research, which has just announced a major expansion into SE Asia – plans to further develop the technologies for licensing to pharmaceutical or generic companies and is actively seeking to become involved in collaborative research with interested parties.
The patents are in the area of controlled drug release and have been demonstrated clinically in the therapeutic areas of cardiovascular disease, pain management and sleep. As a result of the licensing agreement, DDi has already entered into early stage discussions with a global pharmaceutical company to secure a collaborative research agreement with an option to license a controlled release drug formulation for pain control.
DDi, which is based in the medical block of Glasgow Royal Infirmary, employs a staff of world class scientists who have more than 40 years’ experience in drug formulation.
Dr Carol Thomson, Chief Operating Officer of DDi said: “We are delighted to announce this licensing agreement with the University of Strathclyde. The controlled release formulations offer tremendous advantage over existing technologies and we are excited about further developing these and expanding their use to other therapeutic areas.
“This is the first step in Drug Delivery International’s strategy to build and develop a strong IP portfolio and we look forward to continuing our growth in this area.”
The patented technology was developed as part of a Scottish Enterprise funded Proof of Concept project.
The licensing agreements were facilitated by University of Strathclyde’s Research and Knowledge Exchange Services, which manages commercialisation and technology transfer interactions between the University and business and industry.
For more information, please contact Mrs Louise McKean, Contracts Manager at Research and Knowledge Exchange Services on 0141 548 4364 email@example.com.